The Myelin Repair Foundation (MRF), a nonprofit research organization, and ENDECE Neural have formed a partnership to expedite the advancement of myelin regeneration drug candidates for Multiple Sclerosis (MS) patients through pre-clinical studies and into phase I trials.

Through the collaboration, the newly launched MRF Translational Medicine Center will assess the myelin regenerating capabilities of proprietary small molecule compounds from ENDECE Neural in novel MRF MS models for their effectiveness in reversing myelin damage.

"Unlike current MS therapies, which target immune response and inflammation to slow relapses, our drug compounds are promising candidates for remyelination, with the potential to restore muscle control and mobility.  Without remyelination, there can be no cure for MS," said Dr. James Yarger, Ph.D., president of ENDECE Neural. 

"By combining the innovative approach by ENDECE Neural to remyelination and the resources available at the MRF Translational Medicine Center, we can expedite progress toward developing new MS treatments for patients," said Dr. Jay Tung, Ph.D., vice president of drug discovery and research operations at MRF. "We are excited to work with ENDECE Neural since we both share a deep commitment to bringing novel therapeutics to MS patients who simply cannot wait for new cures."